Annexon Inc
Research Annexon Inc (ANNX) on Bullrun: market cap USD 899.21M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANNX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 899.21M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 44.14M
- Free cash flow-USD 183.16M
Valuation Snapshot
latest market cap is USD 899.21M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 206.70M | -USD 186.49M | n/a | -1.34 | USD 162.05M | USD 26.20M | USD 211.65M |
| FY2024 | USD 0 | -USD 138.20M | -USD 118.02M | n/a | -1.01 | USD 49.50M | USD 28.97M | USD 293.11M |
| FY2023 | n/a | -USD 134.20M | -USD 121.34M | n/a | -1.77 | USD 225.11M | USD 31.36M | USD 250.56M |
| FY2022 | n/a | -USD 141.95M | -USD 122.84M | n/a | -2.6 | USD 140.02M | USD 32.86M | USD 231.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 899.21M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 749.80M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 561.13M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 355.36M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 246.25M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 443.06M | n/a | n/a | n/a |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Annexon Inc's market cap?
Annexon Inc's market capitalization is USD 899.21M.
What does Annexon Inc do?
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.